Emerging therapies for the treatment of ulcerative colitis

Expert Opinion on Emerging Drugs
Nicola PuglieseSilvio Danese

Abstract

Introduction: Ulcerative colitis (UC) is a chronic idiopathic autoimmune inflammatory disorder, primarily affecting the gastrointestinal system. There are many patients affected that do not respond well to therapy and many others to which there is a loss of efficacy every year. The proportion of patients who have already experienced anti-TNF therapy is constantly increasing, making the development of new drugs with alternative mechanisms of action an important need for the treatment of UC.Areas covered: This review aims on emerging drugs in the treatment of UC and reviews data on their efficacy and safety.Expert opinion: UC, for many years, comparatively to CD, received little attention for several possible reasons, especially because it was not considered as a progressive disease able to induce irreversible bowel damage. This has led to lower investments by the scientific community and a slower development of therapeutic options for UC. In the past few years, this trend has started to change. In fact, new promising drugs have been developed and others are emerging with positive results. Although many treatment modalities have recently been approved, additional drugs are currently being investigated and will probably be part of...Continue Reading

References

May 5, 2000·The Cochrane Database of Systematic Reviews·L SutherlandK Makiyama
Jun 14, 2001·Lancet·J Parkin, B Cohen
Nov 6, 2002·The Journal of Biological Chemistry·Sudeepta AggarwalAustin L Gurney
Aug 5, 2003·Alimentary Pharmacology & Therapeutics·C K RaynerM A Kamm
Aug 15, 2003·The Cochrane Database of Systematic Reviews·L Sutherland, J K MacDonald
Jun 17, 2005·The New England Journal of Medicine·Brian G FeaganMargaret K Vandervoort
Dec 13, 2005·The New England Journal of Medicine·Paul RutgeertsJean Frédéric Colombel
May 4, 2006·The Journal of Clinical Investigation·Yoichiro Iwakura, Harumichi Ishigame
Oct 13, 2006·The Journal of Experimental Medicine·Sophie HueKevin J Maloy
Jan 13, 2010·Alimentary Pharmacology & Therapeutics·R D CohenJ Chao
Jan 14, 2010·The American Journal of Gastroenterology·Asher KornbluthUNKNOWN Practice Parameters Committee of the American College of Gastroenterology
Oct 12, 2010·Digestive Diseases·Kim L Isaacs
Mar 17, 2011·The American Journal of Gastroenterology·Alexander C FordPaul Moayyedi
Mar 17, 2011·The American Journal of Gastroenterology·Alexander C FordPaul Moayyedi
Apr 7, 2011·Current Drug Targets·Silvio Danese
Nov 4, 2011·The New England Journal of Medicine·Silvio Danese, Claudio Fiocchi
Jan 27, 2012·The New England Journal of Medicine·Daniel Pelletier, David A Hafler
Mar 7, 2012·Expert Review of Clinical Pharmacology·Maggie Ham, Alan C Moss
Jul 31, 2012·Gut·Markus F Neurath, Simon P L Travis
Jun 6, 2013·Gastroenterology·William J SandbornUNKNOWN PURSUIT-SC Study Group
Aug 6, 2013·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Laurent Peyrin-BirouletWendy Kampman
Aug 24, 2013·The New England Journal of Medicine·Brian G FeaganUNKNOWN GEMINI 1 Study Group
May 21, 2014·Current Opinion in Gastroenterology·Harry SokolJacques Cosnes
Aug 12, 2014·The Cochrane Database of Systematic Reviews·Stephen J BickstonBrian G Feagan
Aug 26, 2014·Nature Reviews. Immunology·Sarah L GaffenDaniel J Cua
Sep 10, 2014·Mayo Clinic Proceedings·Joseph D Feuerstein, Adam S Cheifetz
Nov 18, 2014·Expert Opinion on Drug Safety·Cristiano PagniniFabio Cominelli
Aug 26, 2015·The American Journal of Gastroenterology·L Peyrin-BirouletJ-F Colombel
Sep 5, 2015·Mediators of Inflammation·Bruno Rafael Ramos de MattosPatricia Ucelli Simioni
May 6, 2016·The New England Journal of Medicine·William J SandbornUNKNOWN TOUCHSTONE Study Group
May 19, 2016·The Cochrane Database of Systematic Reviews·Antje TimmerJohn K MacDonald
May 21, 2016·Inflammatory Bowel Diseases·Andrew R ReininkPeter D R Higgins
Sep 21, 2016·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Julajak LimsrivilaiPeter D R Higgins
Oct 11, 2016·Gastroenterology·Jean-Frederic ColombelLaurent Peyrin-Biroulet
Nov 20, 2016·Gut·Pablo OliveraLaurent Peyrin-Biroulet
Dec 5, 2016·Lancet·Ryan UngaroJean-Frédéric Colombel

❮ Previous
Next ❯

Citations

Jul 14, 2021·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Cailan LiQiang Lu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Expert Opinion on Emerging Drugs
Luca PastorelliMaurizio Vecchi
Current Gastroenterology Reports
Andrew S Ross, Russell D Cohen
Medicinal Research Reviews
Silvio DaneseRenzo Caprilli
Clinical Investigation
Byron P Vaughn, Alan C Moss
Digestion
Emanuel BurriSwiss IBDnet, an official working group of the Swiss Society of Gastroenterology
© 2021 Meta ULC. All rights reserved